Loading stock data…
MENS
$2.25-0.02 (-0.88%)
Market ClosedLast close May 1
Jyong Biotech Ltd., a science-driven biotechnology company, develops and commercializes plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Jyong Biotech Ltd. in the Healthcare sector is trading at $2.25. The stock is currently near its 52-week low of $1.43, remaining 90.3% below its 200-day moving average. Technical signals show oversold RSI of 25 and bearish MACD signal, explaining why MENS maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 25) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.25
Potential Upside
5%
Whystock Fair Value$2.36
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Jyong Biotech Ltd., a science-driven biotechnology company, develops and commercializes plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops MCS-2 for the treatment of benign...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$173.34M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
8.27%
Volume
Today's trading volume
51,282
Recent News
CEO Fu-Feng Kuo, Jyong Biotech Ltd.'s (NASDAQ:MENS) largest shareholder sees value of holdings go down 23% after recent drop
Key Insights Significant insider control over Jyong Biotech implies vested interests in company growth 52% of the...
Jyong Biotech completes primary endpoint analysis for Phase II trial of MCS-8
Jyong Biotech (MENS) announced that it has achieved another milestone in the development of its plant-derived new drug MCS-8, PCP. The Company has completed the statistical analysis of the primary efficacy endpoints in its ongoing Phase II clinical trial conducted in Taiwan, following the randomized and placebo-controlled trial conducted to over 700 high-risk subjects enrolled into the Phase II clinical trial since its commencement. The data indicated that, compared with placebo, MCS-8 demonstra
Exploring Jyong Biotech’s (NasdaqGM:MENS) Valuation Following Recent Share Price Volatility
Jyong Biotech (NasdaqGM:MENS) has seen some interesting moves in recent sessions, with the stock climbing about 12% yesterday despite no headline news driving the action. Investors appear to be weighing broader sector momentum and possible future catalysts. See our latest analysis for Jyong Biotech. Jyong Biotech’s share price may be up over 224% year-to-date, but recent action shows some volatility, with sharp pullbacks over the past month followed by yesterday’s swift rebound. This...
Evaluating Jyong Biotech (NasdaqGM:MENS): What Recent Price Moves Reveal About Its Current Valuation
Jyong Biotech (NasdaqGM:MENS) is suddenly catching the eye of investors after a recent move in its share price, even without any major event driving headlines. Sometimes stocks stir up attention precisely because there is no clear catalyst, prompting investors to wonder if the market knows something or is simply making a move based on sentiment. Looking at the bigger picture, Jyong Biotech’s momentum has shifted throughout the year. The stock saw an impressive 17.6% gain over the past week...